[
123I
Auger
PARP
radionuclide therapy
radiopharmaceuticals
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
13
01
2023
revised:
24
05
2023
medline:
4
12
2023
pubmed:
29
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Poly(adenosine diphosphate ribose) polymerase (PARP) has emerged as an effective therapeutic strategy against cancer that targets the DNA damage repair enzyme. PARP-targeting compounds radiolabeled with an Auger electron-emitting radionuclide can be trapped close to damaged DNA in tumor tissue, where high ionizing potential and short range lead Auger electrons to kill cancer cells through the creation of complex DNA damage, with minimal damage to surrounding normal tissue. Here, we report on [
Identifiants
pubmed: 37770109
pii: jnumed.123.265429
doi: 10.2967/jnumed.123.265429
pmc: PMC10690119
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Radiopharmaceuticals
0
Iodine-123
8YWR746RPQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1965-1971Informations de copyright
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.
Références
J Nucl Med. 2019 Apr;60(4):504-510
pubmed: 30389822
Genes Cancer. 2010 Aug;1(8):812-21
pubmed: 21779467
Neurooncol Adv. 2020 Sep 15;2(1):vdaa119
pubmed: 33392502
Mol Cancer Ther. 2019 Jul;18(7):1195-1204
pubmed: 31072830
Curr Drug Discov Technol. 2010 Dec;7(4):263-79
pubmed: 21034408
Clin Cancer Res. 2020 Jul 1;26(13):3110-3116
pubmed: 32245901
Biomedicines. 2021 May 18;9(5):
pubmed: 34069967
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3668-3678
pubmed: 35614267
JAMA Oncol. 2020 Jun 1;6(6):921-923
pubmed: 32297911
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Radiology. 2017 Feb;282(2):453-463
pubmed: 27841728
Mol Pharm. 2021 Sep 6;18(9):3418-3428
pubmed: 34318678
J Med Chem. 2021 Nov 11;64(21):15690-15701
pubmed: 34672571
Front Pharmacol. 2020 Mar 03;11:170
pubmed: 32194409
J Nucl Med. 2022 Jan;63(1):44-50
pubmed: 33863820
Clin Cancer Res. 2021 Mar 15;27(6):1585-1594
pubmed: 33082213
JCI Insight. 2021 Apr 22;6(8):
pubmed: 33884961
J Nucl Med. 2018 Aug;59(8):1225-1233
pubmed: 29572254
J Nucl Med. 2022 Sep;63(9):1441-1449
pubmed: 35145016
Clin Cancer Res. 2020 Jun 15;26(12):2871-2881
pubmed: 32066626
ACS Pharmacol Transl Sci. 2021 Jan 26;4(1):344-351
pubmed: 33615184
Org Lett. 2018 Apr 6;20(7):1752-1755
pubmed: 29561158
Eur J Med Chem. 2022 Nov 15;242:114690
pubmed: 36041258
Science. 2020 Apr 3;368(6486):
pubmed: 32241924
Mol Imaging Biol. 2016 Jun;18(3):386-92
pubmed: 26493053
EJNMMI Radiopharm Chem. 2019 Oct 11;4(1):27
pubmed: 31659527
EJNMMI Res. 2022 Oct 9;12(1):67
pubmed: 36210377
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
J Clin Invest. 2018 May 1;128(5):2116-2126
pubmed: 29509546
Molecules. 2020 Dec 19;25(24):
pubmed: 33352773
J Labelled Comp Radiopharm. 2020 Jul;63(9):419-425
pubmed: 32391930
J Nucl Med. 2014 Sep;55(9):1557-64
pubmed: 25012457
Bioorg Med Chem. 2014 Mar 1;22(5):1700-7
pubmed: 24503274
Mol Imaging Biol. 2020 Oct;22(5):1226-1234
pubmed: 32342268
J Nucl Med. 2021 Jun 1;62(6):765-770
pubmed: 33579802
EJNMMI Res. 2022 Sep 14;12(1):60
pubmed: 36104637
Nucl Med Biol. 2016 Dec;43(12):752-758
pubmed: 27689533
Clin Cancer Res. 2023 Apr 14;29(8):1515-1527
pubmed: 36441795
Int J Mol Sci. 2023 Feb 04;24(4):
pubmed: 36834491
Nucl Med Biol. 2023 Jan-Feb;116-117:108312
pubmed: 36621256